First Time Loading...

Edesa Biotech Inc
NASDAQ:EDSA

Watchlist Manager
Edesa Biotech Inc Logo
Edesa Biotech Inc
NASDAQ:EDSA
Watchlist
Price: 4.465 USD 1.94% Market Closed
Updated: Apr 24, 2024

Intrinsic Value

EDSA's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medica... [ Read More ]

The intrinsic value of one EDSA stock under the Base Case scenario is 1.327 USD. Compared to the current market price of 4.465 USD, Edesa Biotech Inc is Overvalued by 70%.

Key Points:
EDSA Intrinsic Value
Base Case
1.327 USD
Overvaluation 70%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Edesa Biotech Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling EDSA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Edesa Biotech Inc

Provide an overview of the primary business activities
of Edesa Biotech Inc.

What unique competitive advantages
does Edesa Biotech Inc hold over its rivals?

What risks and challenges
does Edesa Biotech Inc face in the near future?

Has there been any significant insider trading activity
in Edesa Biotech Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Edesa Biotech Inc.

Provide P/S
for Edesa Biotech Inc.

Provide P/E
for Edesa Biotech Inc.

Provide P/OCF
for Edesa Biotech Inc.

Provide P/FCFE
for Edesa Biotech Inc.

Provide P/B
for Edesa Biotech Inc.

Provide EV/S
for Edesa Biotech Inc.

Provide EV/GP
for Edesa Biotech Inc.

Provide EV/EBITDA
for Edesa Biotech Inc.

Provide EV/EBIT
for Edesa Biotech Inc.

Provide EV/OCF
for Edesa Biotech Inc.

Provide EV/FCFF
for Edesa Biotech Inc.

Provide EV/IC
for Edesa Biotech Inc.

Show me price targets
for Edesa Biotech Inc made by professional analysts.

What are the Revenue projections
for Edesa Biotech Inc?

How accurate were the past Revenue estimates
for Edesa Biotech Inc?

What are the Net Income projections
for Edesa Biotech Inc?

How accurate were the past Net Income estimates
for Edesa Biotech Inc?

What are the EPS projections
for Edesa Biotech Inc?

How accurate were the past EPS estimates
for Edesa Biotech Inc?

What are the EBIT projections
for Edesa Biotech Inc?

How accurate were the past EBIT estimates
for Edesa Biotech Inc?

Compare the revenue forecasts
for Edesa Biotech Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Edesa Biotech Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Edesa Biotech Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Edesa Biotech Inc compared to its peers.

Compare the P/E ratios
of Edesa Biotech Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Edesa Biotech Inc with its peers.

Analyze the financial leverage
of Edesa Biotech Inc compared to its main competitors.

Show all profitability ratios
for Edesa Biotech Inc.

Provide ROE
for Edesa Biotech Inc.

Provide ROA
for Edesa Biotech Inc.

Provide ROIC
for Edesa Biotech Inc.

Provide ROCE
for Edesa Biotech Inc.

Provide Gross Margin
for Edesa Biotech Inc.

Provide Operating Margin
for Edesa Biotech Inc.

Provide Net Margin
for Edesa Biotech Inc.

Provide FCF Margin
for Edesa Biotech Inc.

Show all solvency ratios
for Edesa Biotech Inc.

Provide D/E Ratio
for Edesa Biotech Inc.

Provide D/A Ratio
for Edesa Biotech Inc.

Provide Interest Coverage Ratio
for Edesa Biotech Inc.

Provide Altman Z-Score Ratio
for Edesa Biotech Inc.

Provide Quick Ratio
for Edesa Biotech Inc.

Provide Current Ratio
for Edesa Biotech Inc.

Provide Cash Ratio
for Edesa Biotech Inc.

What is the historical Revenue growth
over the last 5 years for Edesa Biotech Inc?

What is the historical Net Income growth
over the last 5 years for Edesa Biotech Inc?

What is the current Free Cash Flow
of Edesa Biotech Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Edesa Biotech Inc.

Financials

Balance Sheet Decomposition
Edesa Biotech Inc

Current Assets 5.4m
Cash & Short-Term Investments 4.3m
Receivables 743.6k
Other Current Assets 404.9k
Non-Current Assets 2.4m
PP&E 83.1k
Intangibles 2.2m
Other Non-Current Assets 177.7k
Current Liabilities 2m
Accounts Payable 1.9m
Accrued Liabilities 78.3k
Efficiency

Earnings Waterfall
Edesa Biotech Inc

Revenue
0 USD
Operating Expenses
-8.7m USD
Operating Income
-8.7m USD
Other Expenses
988.3k USD
Net Income
-7.7m USD

Free Cash Flow Analysis
Edesa Biotech Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

EDSA Profitability Score
Profitability Due Diligence

Edesa Biotech Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

15/100
Profitability
Score

Edesa Biotech Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.

EDSA Solvency Score
Solvency Due Diligence

Edesa Biotech Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
57/100
Solvency
Score

Edesa Biotech Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

EDSA Price Targets Summary
Edesa Biotech Inc

Wall Street analysts forecast EDSA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EDSA is 24.48 USD with a low forecast of 19.19 USD and a high forecast of 33.6 USD.

Lowest
Price Target
19.19 USD
330% Upside
Average
Price Target
24.48 USD
448% Upside
Highest
Price Target
33.6 USD
653% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

EDSA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

EDSA Price
Edesa Biotech Inc

1M 1M
+7%
6M 6M
+35%
1Y 1Y
-45%
3Y 3Y
-89%
5Y 5Y
-90%
10Y 10Y
-100%
Annual Price Range
4.465
52w Low
2.55
52w High
8.12
Price Metrics
Average Annual Return -14.56%
Standard Deviation of Annual Returns 46.13%
Max Drawdown -97%
Shares Statistics
Market Capitalization 14.1m USD
Shares Outstanding 3 215 970
Percentage of Shares Shorted 0.75%

EDSA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Edesa Biotech Inc Logo
Edesa Biotech Inc

Country

Canada

Industry

Biotechnology

Market Cap

14.1m USD

Dividend Yield

0%

Description

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. The company is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. The company is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.

Contact

ONTARIO
Markham
100 Spy Crt
+19054751234.0
https://www.edesabiotech.com/

IPO

2008-08-25

Employees

16

Officers

CEO, Company Secretary & Director
Dr. Pardeep Nijhawan FRCPC, M.D.
President
Dr. Michael J. Brooks M.B.A., Ph.D.
Chief Financial Officer
Mr. Stephen L. Lemieux BA, CA, CPA, MMPA

See Also

Discover More
What is the Intrinsic Value of one EDSA stock?

The intrinsic value of one EDSA stock under the Base Case scenario is 1.327 USD.

Is EDSA stock undervalued or overvalued?

Compared to the current market price of 4.465 USD, Edesa Biotech Inc is Overvalued by 70%.